key: cord-0830013-laqm357v
authors: Mejia, Erika J.; O'Connor, Matthew J.; Samelson-Jones, Benjamin J.; Mavroudis, Constantine D.; Giglia, Therese M.; Keashen, Rachel; Rossano, Joseph; Naim, Maryam Y.; Maeda, Katsuhide
title: Successful Treatment of Intracardiac Thrombosis in the Presence of Fulminant Myocarditis Requiring ECMO associated with COVID-19
date: 2022-03-10
journal: J Heart Lung Transplant
DOI: 10.1016/j.healun.2022.03.003
sha: d2102c5dc422afb589ad81265b23875d9818c0c5
doc_id: 830013
cord_uid: laqm357v

nan

Coronavirus disease 2019 (COVID-19) is associated with myocardial injury and an increased thrombosis risk. In a meta-analysis of adult hospitalized patients with COVID-19 the odds of mortality were 74% higher with a thrombotic event (TE). 1 Despite thromboprophylaxis, both adult and pediatric patients are at risk for developing a TE. 2,3 COVID-associated myocardial injury can increase risk of intracardiac thrombus and may require extracorporeal membrane oxygenation (ECMO) in severe cases, but optimal treatment and anticoagulation strategies in these situations have not been established.

We report the case of a 17-year-old female with symptomatic COVID-19 who presented in cardiogenic shock and was cannulated to veno-arterial ECMO via the neck. On ECMO day 2, while on therapeutic unfractionated heparin (UFH), a large thrombus was noted in the left ventricular apex, extending toward the aortic valve ( Figure 1 ). There was no additional evidence of deep venous thrombus. Given the concern for thromboembolism, continuous systemic highdose alteplase (tPA) infusion (0.1 mg/kg/hr) was initiated, and UFH was continued. A twentyfold increase in D-dimer levels and serial echocardiograms indicated thrombolytic effect. After 22 hours of thrombolysis, tPA was discontinued as the LV thrombus had diminished in size and the patient developed cannulation site bleeding and a hemothorax. UFH was also subsequently discontinued. That same day a new thrombus was noted by echocardiogram in the right ventricle 

Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C

The use of recombinant tissue-type plasminogen activator in a newborn with an intracardiac thrombus developed during extracorporeal membrane oxygenation

Regional thrombolysis with tenecteplase during extracorporeal membrane oxygenation: a new approach for left ventricular thrombosis

Successful management of neonatal myocardial infarction with ECMO and intracoronary r-tPA lysis

Dr. Erika Mejia receives funding from the National Institute of Health T32 HL1007915